# Nafamostat Efficacy and Safety in Critically Ill Patients(NICE)

> **NCT01486485** · PHASE3 · UNKNOWN · sponsor: **Seoul National University Hospital** · enrollment: 160 (estimated)

## Conditions studied

- Acute Kidney Injury

## Interventions

- **DRUG:** heparinized saline priming group
- **DRUG:** nafamostat infusion after heparinized saline priming

## Key facts

- **NCT ID:** NCT01486485
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-03
- **Primary completion:** 2013-08
- **Final completion:** 2013-08
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2013-02-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01486485

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01486485, "Nafamostat Efficacy and Safety in Critically Ill Patients(NICE)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01486485. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*